TWO PROGRAMS OF CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN THE TREATMENT OF DISSEMINATED COLORECTAL CANCER

TWO PROGRAMS OF CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN THE TREATMENT OF DISSEMINATED COLORECTAL CANCER

The efficiency of 2 programs of chemotherapy in the treatment of 46 patients with disseminated colorectal cancer. The program of chemo-therapy of oxaliplatin + capecitabine (ОХА/САР), established authors, with bevacizumab (BEV) showed the best results compared with oxaliplatin + 5-fluorouracyl + leu...

Full description

Bibliographic Details
Main Authors:	O. V. Zharkova, V. V. Karaseva, V. A. Khailenko, E. B. Mironova, P. S. Feoktistova, K. V. Vyalova, Ya. M. Kolesnikov
Format:	Article
Language:	Russian
Published:	“ABV-press” Publishing house”, LLC 2015-02-01
Series:	Тазовая хирургия и онкология
Subjects:	metastatic colorectal cancer chemotherapy targeted therapy bevacizumab
Online Access:	https://ok.abvpress.ru/jour/article/view/108

Similar Items

CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
by: I. S. Bulavina, et al.
Published: (2015-02-01)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
by: Ocvirk Janja, et al.
Published: (2016-06-01)

Preliminary results of an observational program for estimating the duration of bevacizumab therapy in patients with metastatic colorectal cancer in daily clinical practice
by: I V Poddubnaya, et al.
Published: (2013-03-01)

BEVACIZUMAB COMBINED WITH IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN AS THE FIRST- LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA
by: Deyan Davidov
Published: (2014-12-01)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
by: Yu‐Wen Zhou, et al.
Published: (2021-05-01)

Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy
by: Zhiming Wang, et al.
Published: (2016-09-01)

CLINICAL EXPERIENCE OF COMBINED AVASTIN THERAPY IN METASTATIC COLORECTAL CANCER
by: V. A. Ekimov
Published: (2015-02-01)

The Avastin application in clinical practice in patients with metastatic colorectal cancer: Second interim analysis of the observational AJAX program
by: I V Poddubnaya, et al.
Published: (2014-03-01)

INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG
by: N. V. Dobrova, et al.
Published: (2015-02-01)

Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer
by: Xu R, et al.
Published: (2018-12-01)

BEVACIZUMAB USE IN METASTATIC COLORECTAL CANCER IN THE FACILITIES OF DAY HOSPITAL OF REGIONAL ОNCOLOGY DISPENSARY
by: T. A. Malysheva, et al.
Published: (2015-02-01)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
by: Bożena Cybulska-Stopa, et al.
Published: (2020-03-01)

Prognostic value of <it>KRAS </it>genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
by: Bruera Gemma, et al.
Published: (2012-11-01)

Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study
by: Girolamo Ranieri, et al.
Published: (2017-07-01)

Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
by: Mahmoud A. Elshenawy, et al.
Published: (2020-07-01)

Results of preoperative antitumor therapy in combination with bevacizumab and KRAS status during liver resections for colorectal cancer metastases
by: M I Sekacheva, et al.
Published: (2013-06-01)

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
by: Cheng, C.-L, et al.
Published: (2022)

Modern possibilities of targeted therapy in metastatic colorectal cancer
by: V A Gorbunova
Published: (2015-12-01)

Long-Term Colon Stent Patency for Obstructing Colorectal Cancer Combined with Bevacizumab
by: Anouk E.J. Latenstein, et al.
Published: (2017-11-01)

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature
by: Stein Alexander, et al.
Published: (2012-08-01)

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
by: Zhengwu Sun, et al.
Published: (2020-03-01)

Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
by: Albert Tuca, et al.
Published: (2020-12-01)

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)
by: Angela Damato, et al.
Published: (2020-08-01)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
by: Paola Ulivi, et al.
Published: (2017-06-01)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018-05-01)

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
by: Bobo Zheng, et al.
Published: (2019-03-01)

Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study
by: Girolamo Ranieri, et al.
Published: (2020-11-01)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
by: Alessandro Ottaiano, et al.
Published: (2019-08-01)

Corrigendum: Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study
by: Girolamo Ranieri, et al.
Published: (2021-02-01)

EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION
by: N. Z. Sherman, et al.
Published: (2015-02-01)

Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
by: Ningning Liu, et al.
Published: (2020-04-01)

Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer
by: Jiang C, et al.
Published: (2018-09-01)

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
by: Pectasides Dimitrios, et al.
Published: (2012-06-01)

Clinical case use bevacizumab for patient with metastatic ovarian cancer
by: M. R. Oganyan, et al.
Published: (2014-07-01)

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
by: Jorge Aparicio, et al.
Published: (2020-11-01)

Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients
by: Masatsune Shibutani, et al.
Published: (2018-11-01)

Efferent therapy in the first-line drug treatment of metastatic colorectal cancer
by: Z. S. Kotova, et al.
Published: (2018-07-01)

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
by: Masahito Kotaka, et al.
Published: (2016-12-01)

Pharmacoeconomic-guided choice of systemic chemotherapy in metastatic colorectal cancer patients
by: M. Yu. Fedyanin, et al.
Published: (2017-09-01)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
by: Di Bartolomeo M, et al.
Published: (2015-01-01)